• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EPRX

    Eupraxia Pharmaceuticals Inc.

    Subscribe to $EPRX
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Eupraxia Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    See more ratings

    Eupraxia Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

      SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

      11/14/24 4:17:44 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

      SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

      11/7/24 4:10:15 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    Eupraxia Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/7/25 2:15:04 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/6/25 4:59:51 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/5/25 7:15:04 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      4/24/25 5:10:03 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 40-F filed by Eupraxia Pharmaceuticals Inc.

      40-F - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      3/20/25 4:55:17 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      2/25/25 7:48:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      2/18/25 7:02:02 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      11/20/24 8:57:32 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      11/14/24 5:00:31 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      11/13/24 5:01:36 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    Eupraxia Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Eupraxia Pharmaceuticals Announces CFO Succession

      -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

      2/18/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

      VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

      10/31/24 7:36:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    Eupraxia Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

      VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader (KOL) event on Friday, May 9, 2025 at 9:00 AM ET. To register, click here. The event will feature Evan Dellon, MD, MPH (University of North Carolina, Chapel Hill), who will join Company management to discuss additional clinical data from Eupraxia's Phase 1b/2a RESOLVE Study evaluating EP-104GI for the treatment of

      5/7/25 2:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

      Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

      5/6/25 6:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

      Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoEAlso, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month resultsAdditional long-term data to be released with higher doses in Q3 2025Eupraxia to host webinar with guest, Dr. Evan Dellon, to discuss data from RESOLVE trial on Fri

      5/5/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

      VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company's management and scientific teams will present at the following investor and scientific conferences in April and May: Osteoarthritis Research Society International World Congress April 24-27, 2025 Dr. Phil Conaghan, a member of the Company's OA Clinical Advisory Board, will be presenting a poster on the Company's behalf at the Os

      4/24/25 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

      VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

      3/20/25 5:30:48 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

      Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increaseCohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeksCohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeksCohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to dateCohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at 24 weeks, showing continuously improving symptom relief over that timeFor tissue health (EoEHSS) and PEC there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 showing the greatest

      2/25/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces CFO Succession

      -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

      2/18/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

      DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safetyIn clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagitis or osteoarthritisDiffuSphere™ has shown its versatility with various drug classes, supporting the possibility to treat multiple types of pain, infectious diseases, eye diseases and cancersVICTORIA, BC, Nov. 20, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biote

      11/20/24 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

      VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the American College of Rheumatology (the "ACR") Convergence 2024 Annual Meeting, being held in Washington, D.C. from November 14-19, 2024. The Annual Meeting is a premier annual rheumatology event hosted by the ACR. Th

      11/14/24 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

      EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalenceRegistration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.comVICTORIA, BC, Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Even

      11/13/24 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    Eupraxia Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

      Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

      5/6/25 6:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

      VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

      3/20/25 5:30:48 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

      VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the third quarter, we advanced our Phase 1b/2a RESOLVE trial for EP-104GI as a treatment for eosinophilic esophagitis, reporting further positiv

      11/7/24 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

      VICTORIA, BC, Aug. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study conti

      8/7/24 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    Eupraxia Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Eupraxia Pharmaceuticals with a new price target

      Craig Hallum initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      2/21/25 8:14:31 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Rodman & Renshaw initiated coverage on Eupraxia Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      11/14/24 7:29:37 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care